Business Context and Reporting Period
This Form 8-K is a current report filed by Mangoceuticals, Inc. (MGRX), a Texas corporation listed on the Nasdaq Capital Market. The report covers events occurring on March 28, 2025, and April 2, 2025, with the filing date of April 8, 2025. The company is designated as an emerging growth company.
Key Financial Metrics and Capital Structure Changes
The filing details specific unregistered sales of equity securities involving the conversion of preferred stock and debt into common stock. No revenue, profit, cash flow, or margin data is provided in this document.
- Series B Conversion: 350 shares of Series B Convertible Preferred Stock (aggregate stated value: $385,000) were converted into 256,666 shares of common stock at a price of $1.50 per share.
- Debt Conversion: $500,000 of debt owed to MAAB Global Ltd. (previously owed to Barstool Sports Inc.) was converted into 333,333 shares of common stock at a price of $1.50 per share.
- Total New Shares Issued: 590,000 shares of common stock were issued in these transactions.
Material Changes Versus Prior Period
This filing does not provide comparative financial data or a discussion of material changes in operating results versus prior periods. The primary material change is the reduction of debt and preferred equity obligations in exchange for an increase in outstanding common shares.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future outlook, or specific risk factors beyond the standard disclosure of the transactions. The company claims an exemption from registration under Section 3(a)(9) of the Securities Act of 1933, noting that no commission or remuneration was paid for soliciting the exchange.
Investor Verification Checklist
- Verify the updated total number of outstanding common shares following the issuance of 590,000 new shares.
- Confirm the current status of the $500,000 debt obligation to MAAB Global Ltd. to ensure it is fully extinguished.
- Review the terms of the Series B Convertible Preferred Stock to understand remaining conversion rights for other holders.
- Check for any subsequent filings regarding the impact of this dilution on earnings per share (EPS).